CARE Ratings reaffirms Omaxe at CARE BB+
Omaxe (OMAXE) said CARE Ratings has reaffirmed its credit rating at CARE BB+. The company is valued at about ₹1,832 crore.
What happened
In a filing with the BSE on 12 October 2026 at 06:25 PM, Omaxe (OMAXE) said that CARE Ratings has reaffirmed its credit rating at CARE BB+.
From the filing: "The details of aforesaid credit ratings are indicated below: Credit Rating Type of Credit Rating Rating Rating Action A2encv CARE Ratings Long-term I short-term bank facilities CARE BB+;"
Company snapshot
Omaxe is a small-cap company, with a market value of about ₹1,832 crore.
The stock last traded at ₹100.2, against a 52-week range of ₹62.5–₹138.9 (27.9% below the high).
Before this filing the shares had moved −17.4% over the month and +10.4% over three months. Average daily turnover over the last 20 sessions was about ₹6.82 crore.
Promoters held 74.14% at the end of Q1 FY27; 41.02% of promoter shares were pledged. Foreign institutions owned 5.33% and domestic institutions 1.40%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 282 | -185.8 | -10.16 |
| Q2 FY26 | 321 | -166.6 | -9.11 |
| Q3 FY26 | 302 | -153.2 | -8.38 |
| Q4 FY26 | 349 | -191.3 | -10.46 |
| Q1 FY27 | 406 | 0.9 | 0.05 |
What history shows
This is not the company's first credit rating disclosure: BCEIE has 1 earlier filing of this kind on record since May 2026.
Market-wide, 1,260 credit rating filings with an impact score of 50 or more saw an average next-day move of +0.1%, with 47% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Whether other agencies take a similar view on the company's credit.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.